Physician
Alma S. Rigonan, MD, PA
Alma S. Rigonan, MD, PA was paid $4.37M by Medicaid between Jan 2018 and Dec 2024, across 64 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 24% of everything it billed.
33Billing provider infoALMA S. RIGONAN, MD, PA
CORPUS CHRISTI, TX 78411
CORPUS CHRISTI, TX 78411
33aNPI1932154101assigned 05/24/2006
28Total paid$4.37M
24GClaims141,939
24DCodes billed64
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,673 | $13K | |
| 2019 | 1,809 | $12K | |
| 2020 | 4,856 | $125K | |
| 2021 | 30,056 | $904K | |
| 2022 | 35,977 | $1.11M | |
| 2023 | 34,836 | $1.11M | |
| 2024incomplete | 32,732 | $1.09M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 24% | 21,983 | 19,966 | $1.05M |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | 16% | 5,747 | 5,661 | $677K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 8.5% | 8,667 | 8,057 | $369K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 6.8% | 8,950 | 8,284 | $296K |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | 4.0% | 888 | 513 | $172K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 3.6% | 1,964 | 1,945 | $157K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 3.4% | 1,952 | 1,905 | $150K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 3.4% | 1,794 | 1,774 | $149K |
| 95115 | 3.3% | 24,007 | 6,268 | $145K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 2.9% | 1,730 | 1,687 | $129K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 2.6% | 3,949 | 3,805 | $114K |
| 99244 | Office or other outpatient consultation, moderate to high complexity | 2.5% | 1,026 | 1,016 | $108K |
52 more codes
| 87428 | 2.3% | 1,398 | $101K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.9% | 6,130 | $83K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 1.9% | 1,102 | $81K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 1.8% | 7,465 | $80K |
| 96900 | 1.6% | 4,615 | $72K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.5% | 4,898 | $67K |
| 95117 | 1.4% | 7,465 | $62K | |
| 99204 | Doctor's office visit, new patient (more involved) | 1.4% | 772 | $60K |
| 87581 | <1% | 1,517 | $44K | |
| 87807 | <1% | 3,368 | $36K | |
| 87634 | <1% | 679 | $33K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,178 | $32K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 2,010 | $16K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 2,037 | $13K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 385 | $9K |
| 90461 | <1% | 3,632 | $9K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 150 | $8K |
| 92567 | <1% | 524 | $7K | |
| 17110 | <1% | 71 | $6K | |
| 94060 | <1% | 183 | $6K | |
| 99051 | <1% | 1,251 | $6K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 92 | $5K |
| 96160 | <1% | 2,018 | $4K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 322 | $3K |
| 81002 | <1% | 1,112 | $3K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 233 | $3K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 17 | $1K |
| 99384 | <1% | 13 | $1K | |
| 99242 | <1% | 18 | $1K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 13 | $1K |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 85 | $523.71 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 30 | $460.32 |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 35 | $274.40 |
| 90686 | <1% | 603 | $37.11 | |
| 90651 | <1% | 401 | $0.07 | |
| 90620 | <1% | 41 | $0.06 | |
| 90734 | <1% | 421 | $0.05 | |
| 90656 | <1% | 27 | $0.02 | |
| 90677 | <1% | 227 | $0.02 | |
| 90680 | 0% | 428 | $0.00 | |
| 90716 | 0% | 195 | $0.00 | |
| 90697 | 0% | 52 | $0.00 | |
| 90723 | 0% | 112 | $0.00 | |
| 90696 | 0% | 13 | $0.00 | |
| 90698 | 0% | 13 | $0.00 | |
| 90648 | 0% | 241 | $0.00 | |
| 90670 | 0% | 818 | $0.00 | |
| 90633 | 0% | 404 | $0.00 | |
| 90715 | 0% | 125 | $0.00 | |
| 90700 | 0% | 54 | $0.00 | |
| 90710 | 0% | 116 | $0.00 | |
| 90707 | 0% | 173 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRIGONAN, ALMA (PRESIDENT/OWNER)